

Figure 3 Diverse IgG antibody response patterns in sera from TB patients. Serum numbers: (A) 19; (B) 23; (C) 39; (D) 48; (E) 5; (F) 10; (G) 60; (H) 55; (I) 42; (J) 36; and (K) 62. Detailed clinical backgrounds are listed in Table 1. All ELISA conditions were the same and are described in the text.

terial lipid antigens, we compared the positive rate and average IgG antibody titers against each single and total (multiple) antigens, according to the degree of antigen stimulation. In general, the positive rate and average IgG antibody titers against each lipid antigen were paralleled by the amount of acid-fast bacilli excreted, based on the smear test. Patients who excreted more acid-fast bacilli in sputum on first examination clearly showed higher positive rates and higher average titers in IgG antibody responses (Table 3). Anti-TDM-T IgG antibody responses showed a marked difference in positive rate and average IgG antibody titers between smear-negative (–) and -positive (\pm and +1) or high smear score (+2 and +3) groups. In contrast, anti-TMM-T IgG antibody responses showed a smaller difference in positive rate and average IgG antibody titers between smear-negative (–) and -positive (\pm and +1) groups. These results indicate that the elevation of IgG antibody

titers against mycobacterial lipid antigens, especially those against TDM-T, is strongly related to the amount of acid-fast bacteria excreted.

Effect of the extent of pathological lesions (cavity-positive or -negative) on IgG antibody responses

We compared the positive rate and average IgG antibody titers against each single and total (multiple) antigens for patient groups with different degrees of pathological lesion by chest X-ray examination. Generally, patients with larger or more severe pathological lesions showed higher positive rates and higher average titers for IgG antibody responses (Table 4). In the case of anti-TDM-T IgG antibodies, there was a marked difference in the positive rate and average IgG antibody titer between cavity (I and II) and non-cavity (III) groups. In the case of anti-Ac-PIM₂ and anti-TMM-T IgG antibodies, there were smaller, but

Table 3 Effect of excreting amount of acid-fast bacteria on positive rate and IgG antibody levels.

Antigen		Bacterial burden smear			
		–	\pm and +1	+2 and +3	Total
Ac-PIM ₂	Positive/total	5/14	11/20	25/35	41/69
	Sensitivity, %	35.7	55.0	71.4	59.4
	Δ OD	0.527 \pm 0.754	0.640 \pm 0.522	1.214 \pm 0.981	
TDM-T	Positive/total	1/14	12/20	19/35	32/69
	Sensitivity, %	7.1	60.0	54.3	46.4
	Δ OD	0.052 \pm 0.109	0.473 \pm 0.542	0.857 \pm 1.068	
TMM-T	Positive/total	5/14	7/20	17/35	29/69
	Sensitivity, %	35.7	35.9	48.6	42.0
	Δ OD	0.166 \pm 0.293	0.197 \pm 0.196	0.535 \pm 0.766	
Total	Positive/total	6/14	16/20	27/35	49/69
	Sensitivity, %	42.9	80.0	77.1	71.0

Δ OD values are mean \pm SD.

Table 4 Effect of size and severity of pathological lesions on the positive rate and IgG antibody levels.

Antigen		Pathological lesion				Total
		I + bII (cavity+)	bIII (cavity-)	1 or rIII (cavity-)	Other types/ unknown	
Ac-PIM ₂	Positive/total	21/30	11/20	8/16	1/3	41/69
	Sensitivity, %	70.0	55.0	50.0	33.3	59.4
	ΔOD	1.120±0.952	0.702±0.690	0.744±0.824		
TDM-T	Positive/total	19/30	10/20	2/16	1/3	32/69
	Sensitivity, %	63.3	50.0	12.5	33.3	46.4
	ΔOD	0.828±0.956	0.550±0.803	0.237±0.740		
TMM-T	Positive/total	15/30	9/20	3/16	2/3	29/69
	Sensitivity, %	50.0	45.0	18.9	66.7	42.0
	ΔOD	0.421±0.599	0.362±0.565	0.233±0.655		
Total	Positive/total	24/30	15/20	8/16	2/3	49/69
	Sensitivity, %	80.0	75.0	50.0	66.7	71.0

ΔOD values are mean ± SD.

Table 5 Effect of age on the positive rate and IgG antibody levels.

Antigen		Age, years				Total
		20-34	35-49	50-64	>65	
Ac-PIM ₂	Positive/total	9/21	10/15	13/15	9/18	41/69
	Sensitivity, %	42.9	66.7	86.7	50.0	59.4
	ΔOD	0.520±0.565	0.901±0.829	1.504±0.987	0.870±0.896	
TDM-T	Positive/total	10/21	4/15	10/15	8/18	32/69
	Sensitivity, %	47.6	26.7	66.7	44.4	46.4
	ΔOD	0.545±0.827	0.286±0.625	0.784±0.949	0.704±1.011	
TMM-T	Positive/total	10/21	6/15	6/15	7/18	29/69
	Sensitivity, %	47.6	40.0	40.0	38.9	42.0
	ΔOD	0.219±0.228	0.261±0.302	0.600±0.856	0.453±0.753	
Total	Positive/total	14/21	11/15	13/15	11/18	49/69
	Sensitivity, %	66.7	73.3	86.7	61.1	71.0

ΔOD values are mean ± SD.

distinctive differences in the positive rate and average IgG antibody titer between cavitory (I and II) and non-cavitory (III) groups. These results indicate that the elevation of IgG antibody titers against mycobacterial lipid antigens, especially those against TDM-T, is strongly related to the progression of active TB.

Effect of age on IgG antibody responses

We compared the positive rate and average IgG antibody titer against each single and total (multiple) antigens among patient groups with different ages (Table 5). Among four different age groups (20-34, 35-49, 50-64, and >65 years), the total (cumulative) positive rate ranged from 66.7% to 86.7%, with the 50-64 years group showing the highest rate. The group >65 years showed a 61.1% positive rate. Average IgG antibody titers for anti-Ac-PIM₂, anti-TDM-T and anti-

TMM-T IgG antibodies were highest in the 50-64 years group, while the group >65 years also showed considerably high levels. Therefore, the multiple-antigen ELISA is useful for the diagnosis of active TB in senile patients.

IgG antibody responses of TST-negative or diabetes mellitus-TB patients against mycobacterial lipid antigens

To evaluate humoral antibody responses against mycobacterial lipid antigens in patients whose cell-mediated immunity may have been suppressed, we estimated IgG antibody titers against mycobacterial lipid antigens in TST-negative patient sera. Three of five TST-negative TB suspects who had a positive or negative smear and marked chest X-ray lesions showed a positive result in the multiple-antigen ELISA

Table 6 IgG antibody responses in TST-negative TB patients.

Serum number	IgG antibodies against			Total	TST	
	Ac-PIM ₂	TDM-T	TMM-T		Induration	Erythema
10	+	-	+	+	0	0
19	+	+	+	+	0	0
28	-	-	-	-	0	0
55	+	+	-	+	0	17×11
62	-	-	-	-	0	4×3

Table 7 IgG antibody responses in diabetes mellitus TB patients.

Serum number	IgG antibodies against			Total	TST	
	Ac-PIM ₂	TDM-T	TMM-T		Induration	Erythema
11	+	+	+	+	47×32	69×44
12	-	+	-	+	25×23	26×26
31	+	-	-	+	22×22	22×22
35	-	-	-	-	35×26	40×29
37	+	+	+	+	10×10	13×18
46	+	+	+	+	30×22	35×27
49	+	+	-	+	4×4	8×8
59	-	-	-	-	13×12	13×12

(Table 6). Furthermore, six of eight diabetes mellitus-TB patients who also had a distinctive pathological lesion showed a positive result (Table 7). Taken together, and differing from the TST based on cell-mediated immunity, humoral IgG antibody responses against mycobacterial lipid antigens seem to show greater correlation to the bacterial burden and disease progression and thus are more sensitive for the diagnosis of active TB disease.

Discussion

The immunological responses of human patients infected with *M. tuberculosis* have been extensively investigated from the aspect of cell-mediated immunity, and the TST has long been used as the most useful tool for the immunodiagnosis of TB infection. However, it has been established that only 5–10% of TB-infected individuals develop the active disease. Most young people are given the BCG vaccination before school age in Japan, and the TST cannot differentiate between latent TB infection and BCG vaccination. Furthermore, once infected with *M. tuberculosis*, TST positivity continues for a long time and therefore the test is not useful to differentiate recent infection or old TB. TST cannot differentiate the *Mycobacterium* species involved, such as *M. tuberculosis*, *M. avium* complex or BCG vaccination because of the high cross-reactivity of protein antigens, and thus it is not suitable for the diagnosis of active TB disease. Modern anti-TB chemotherapy is effective in curing the active disease if initiated properly in the early stages of the disease and chemoprophylaxis is vital for high-risk contact groups who might develop the active disease without such therapy; thus, proper diagnosis using a reliable diagnostic tool is essential. Furthermore, TST may affect the immunological status of patients when it is repeatedly applied due to the booster effect.

Studies on serodiagnosis in human patients infected with *M. tuberculosis* have long been carried out since Arloing first reported on the agglutination test in 1898 (17). However, owing to the low positive rate and low specificity of humoral responses to purified protein derivative (PPD) and other protein antigens (3, 8), the diagnostic value of such responses has not been thoroughly evaluated in the clinical field. Recent developments in serodiagnostics using multiple-pro-

tein antigens have yielded considerable improvements in sensitivity and specificity for the early diagnosis of TB disease (18, 19). However, the overall sensitivity of a multi-antigen ELISA test with 10 protein antigens (combi-10) has been reported to be at 70% at best (18).

Humoral immune responses in human TB infection against lipid antigens are poorly understood, despite the large amount and various types of lipid molecules constructed in the surfaces of mycobacterial cell walls.

In the present study, we expected that a combination of appropriate lipid antigens would give much higher sensitivity for the diagnosis of active TB in both smear-positive and -negative cases. We selected and combined three representative lipid antigens from *M. bovis* BCG Tokyo 172, and when an overall positive was scored if any one of the three tests was positive, markedly higher sensitivity was obtained, although the total (cumulative) sensitivity of IgG antibody responses did not reach 100%. However, IgG antibody positive rates for TB patient sera against the three lipid antigens in the present study showed higher values than the rates for Determinar TBGL and MycoDot tests in the same patient population.

In our previous study, we first reported that anti-*M. tuberculosis* cord factor IgG antibody titers were significantly elevated in active TB patient sera (11) and demonstrated that the detection of anti-cord factor antibody was applicable to the early diagnosis of active pulmonary TB (12), colon TB (20) and later TB uveitis (21). A TBGL (tuberculous glycolipid) antibody detection system using mainly cord factor with minor glycolipid antigens derived from *M. tuberculosis* H₃₇Rv has been developed (22) and was clinically evaluated in a multicenter study to be useful for the diagnosis of TB in the early stages of the disease (23). The cord factor of *M. bovis* BCG Tokyo 172 possesses similar subclasses and molecular species of mycolic acid (α -, methoxy- and keto-mycolates) to those of *M. tuberculosis*, and the preparation of lipid antigens from *M. bovis* BCG Tokyo 172 is much easier than for those from *M. tuberculosis*. Therefore, *M. bovis* BCG Tokyo 172 cord factor (TDM-T) is useful as a diagnostic antigen for mycobacteriosis, including TB. It was especially noted that the elevation of IgG antibody titers against particular lipid antigen differed greatly and individually. Some patients showed high positivity against all three antigens generally. However,

some patients show high positivity against only the mycoloyl glycolipids (TDM-T and TMM-T), whereas others were positive against only the phospholipid (Ac-PIM₂). Some were positive to TMM-T, but not to TDM-T, indicating that not only the carbohydrate moiety, but also the mycoloyl residues or acyl numbers of the trehalose esters was exclusively recognized, as we have already reported for recognition of the mycolic acid structure (24). Recently, lipid-antigen presenting molecules group 1-CD1 (such as CD1a, CD1b and CD1c) and group 2-CD1 (CD1d and CD1e) in human dendritic cells or macrophages were investigated (25–27), and T-cell responses in humans infected with *M. tuberculosis* to CD-1 restricted lipid antigens were reported (28). However, lipid antigen presentation to B-cells in humoral immune responses has not yet been reported. Mycobacterial lipid antigen epitopes may be presented by novel mechanisms different from the classical MHC class I and class II restricted protein antigens.

To improve the ELISA sensitivity, we also evaluated a combination of mycobacterial glycolipids. Combinations of three types of TDM (TDM from *M. tuberculosis* H₃₇Rv, *M. bovis* BCG Connaught and *M. avium* complex) and three types of TMM (TMM from *M. tuberculosis* H₃₇Rv, *M. bovis* BCG Connaught and *M. avium* complex) as ELISA antigens gave 90% (36/40) positive results in sera from 40 active TB patients (data not shown). Furthermore, an additional combination of diacyl phosphatidylinositol dimannosides and phenol glycolipids (PGL-O and -K) from *M. tuberculosis* Aoyama B surprisingly gave a 97.5% (39/40) positive result (data not shown). This suggests that mycobacterial lipid antigens can be recognized distinctively and individually in sera from TB patients and multiplication of lipid antigens in an ELISA could possibly give better discriminating power serologically.

In a separate paper (29) based on the quantitative analysis of anti-mycobacterial lipid antibodies, we reported that IgG antibody titers in TB patient sera varied greatly according to the stage of the disease. This differs from the TST result, which shows a long-lasting positive once changed to positive from negative.

Patients with a positive smear showed higher positive rates and higher average IgG antibody titers, indicating that IgG antibody responses reflect well the bacterial burden. IgG antibody responses were also related to the severity and size of pathological lesions identified by chest X-ray. In general, patients with larger and more severe pathological lesions showed higher positive rates against all three antigens, while patients with smaller or less severe lesions showed lower rates.

In our study, we tested antibody titers of suspected TB patients, rather than patients in hospital, and therefore subjects were in the early stages of the active disease with minimal clinical symptoms and preliminary chest X-ray results. However, our multiple-antigen ELISA still showed higher positive rates than other serodiagnostic kits, and immune-suppressed

patients such as TST-negative and diabetes mellitus-TB patients showed antibody positivity, irrespective of age. Taken together, a multiple-antigen ELISA based on humoral immune responses may be the most useful tool for the rapid diagnosis of active disease due to mycobacterial infection, even for TST-negative cases and subjects in an immunosuppressed state. To establish the most reliable serodiagnosis, tests with higher sensitivity and specificity based on the best combination of antigens need to be identified.

References

1. Grange JM, Gibson J, Nassau E, Kardjito T. Enzyme-linked immunosorbent assay (ELISA): a study of antibodies to *Mycobacterium tuberculosis* in the IgG, IgA and IgM classes in tuberculosis, sarcoidosis and Crohn's disease. *Tubercle* 1980;61:145–52.
2. Jagannath C, Sengupta DN, Bahadur P. Serology of tuberculosis. II. Measurement of antibodies to *Mycobacterium tuberculosis* by a passive haemagglutination test in human tuberculosis. *Tubercle* 1983;64:201–10.
3. Benjamin RG, Debanne SM, Ma Y, Daniel TM. Evaluation of mycobacterial antigens in an enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of tuberculosis. *J Med Microbiol* 1984;18:309–18.
4. Kiran U, Shrinivas, Kumar R, Sharma A. Efficacy of three mycobacterial antigens in the serodiagnosis of tuberculosis. *Eur J Respir Dis* 1985;66:187–95.
5. Benjamin RG, Daniel TM. Serodiagnosis of tuberculosis using the enzyme-linked immunosorbent assay (ELISA) of antibody to *Mycobacterium tuberculosis* antigen 5. *Am Rev Respir Dis* 1982;126:1013–6.
6. Stroebel AB, Daniel TM, Lau JH, Leong JC, Richardson H. Serologic diagnosis of bone and joint tuberculosis by an enzyme-linked immunosorbent assay. *J Infect Dis* 1982;146:280–3.
7. Reggiardo Z, Middlebrook G. Serologically active glycolipid families from *Mycobacterium bovis* BCG. I. Extraction, purification and immunologic studies. *Am J Epidemiol* 1974;100:469–76.
8. Daniel TM, Debanne SM. The serodiagnosis of tuberculosis and other mycobacterial diseases by enzyme-linked immunosorbent assay. *Am Rev Respir Dis* 1987;135:1137–51.
9. Chan ED, Heifets L, Iseman MD. Immunologic diagnosis of tuberculosis: a review. *Tubercle Lung Dis* 2000;80:131–40.
10. WHO. Modelling the impact of new diagnostic technologies in disease endemic countries. *TBDI Activity Summary*. May 2001:1–5.
11. He H, Oka S, Han YK, Yamamura Y, Kusunose E, Kusunose M, et al. Rapid serodiagnosis of human mycobacteriosis by ELISA using cord factor (trehalose-6,6'-dimycolate) purified from *Mycobacterium tuberculosis* as antigen. *FEMS Microbiol Immunol* 1991;3:201–4.
12. Maekura R, Nakagawa M, Nakamura Y, Hiraga T, Yamamura Y, Ito M, et al. Clinical evaluation of rapid serodiagnosis of pulmonary tuberculosis by ELISA with cord factor (trehalose-6,6'-dimycolate) as antigen purified from *Mycobacterium tuberculosis*. *Am Rev Respir Dis* 1993;148:997–1001.
13. Enomoto K, Oka S, Fujiwara N, Okamoto T, Okuda Y, Maekura R, et al. Rapid serodiagnosis of *Mycobacterium avium*-intracellulare complex infection by ELISA with cord factor (trehalose 6,6'-dimycolate), and serotyping

- using the glycopeptidolipid antigen. *Microbiol Immunol* 1998;42:689–96.
14. Iinuma Y, Senda K, Takakura S, Ichiyama S, Tano M, Abe T, et al. Evaluation of a commercially available serologic assay for antibodies against tuberculosis-associated glycolipid antigen. *Clin Chem Lab Med* 2002;40:832–6.
 15. Maekura R, Kohno H, Hirotsu A, Okuda Y, Ito M, Ogura T, et al. Prospective clinical evaluation of the serologic tuberculosis glycolipid test in combination with the nucleic acid amplification test. *J Clin Microbiol* 2003;41:1322–5.
 16. Anderson RJ. The chemistry of the lipoids of the tubercule bacillus and certain other microorganisms. In: Zechmeister L, editor. *Progress in the chemistry of organic natural products*, vol 3. Vienna: Springer, 1939:145–202.
 17. Arloing S. Agglutination de bacille de la tuberculose vraie. *C R Acad Sci* 1898;126:1398–400.
 18. Lyashchenko K, Manca C, Colangeli R, Heijbel A, Williams A, Gennaro ML. Use of *Mycobacterium tuberculosis* complex-specific antigen cocktails for a skin test specific for tuberculosis. *Infect Immun* 1998;66:3606–10.
 19. Lyashchenko KP, Singh M, Colangeli R, Gennaro ML. A multi-antigen print immunoassay for the development of serological diagnosis of infectious diseases. *J Immunol Methods* 2000;242:91–100.
 20. Kashima K, Oka S, Tabata A, Yasuda K, Kitano A, Kobayashi K, et al. Detection of anti-cord factor antibodies in intestinal tuberculosis for its differential diagnosis from Crohn's disease and ulcerative colitis. *Dig Dis Sci* 1995;40:2630–4.
 21. Sakai J, Matsuzawa S, Usui M, Yano I. New diagnostic approach for ocular tuberculosis by ELISA using the cord factor as antigen. *Br J Ophthalmol* 2001;85:130–3.
 22. Kawamura M, Sueshige N, Imayoshi K, Yano I, Maekura R, Kohno H. Enzyme immunoassay to detect antituberculous glycolipid antigen (anti-TBGL antigen) antibodies in serum for diagnosis of tuberculosis. *J Clin Lab Anal* 1997;11:140–5.
 23. Maekura R, Okuda Y, Nakagawa M, Hiraga T, Yokota S, Ito M, et al. Clinical evaluation of anti-tuberculous glycolipid immunoglobulin G antibody assay for rapid serodiagnosis of pulmonary tuberculosis. *J Clin Microbiol* 2001;39:3603–8.
 24. Pan J, Fujiwara N, Oka S, Maekura R, Ogura T, Yano I. Anti-cord factor (trehalose 6,6'-dimycolate) IgG antibody in tuberculosis patients recognizes mycolic acid subclasses. *Microbiol Immunol* 1999;43:863–9.
 25. Porcelli S, Morita CT, Brenner MB. CD1b restricts the response of human CD4-8-T lymphocytes to a microbial antigen. *Nature* 1992;360:593–7.
 26. Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, Brenner MB. Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. *Nature* 1994;372:691–4.
 27. Moody DB, Reinhold BB, Guy MR, Beckman EM, Frederique DE, Furlong ST, et al. Structural requirements for glycolipid antigen recognition by CD1b-restricted T cells. *Science* 1997;278:283–6.
 28. Ulrichs T, Moody DB, Grant E, Kaufmann SH, Porcelli SA. T-cell responses to CD1-presented lipid antigens in humans with *Mycobacterium tuberculosis* infection. *Infect Immun* 2003;71:3076–87.
 29. Fujita Y, Doi T, Sato K, Yano I. Diverse humoral immune responses and changes in IgG antibody levels against mycobacterial lipid antigens in active tuberculosis. *Microbiology* 2005;151:2065–74.

Received May 9, 2005, accepted August 23, 2005

肺結核診断におけるプロテオミクス

Proteomic and diagnostic analysis of tuberculous antigens

日本ビーシージー製造株式会社中央研究所所長 矢野 郁也 *Ikuya Yano*

Key words

結核感染と発病の診断, ツベルクリン皮内反応, 細胞性免疫, 体液性免疫, 結核菌抗原のプロテオーム解析, ESAT-6ファミリー分泌抗原

Summary

結核は現在でも人類に蔓延する伝染病の中で最も重要なものの1つであり, AIDSや免疫不全患者では予後が悪く早期の診断・治療・予防が必要である。ツベルクリン反応はきわめて感度の高い皮膚反応で, 細胞性免疫の指標として長年用いられてきたが, 一方で抗酸菌共通抗原を多数含むため交叉反応性が強く, 結核かまたは他の抗酸菌感染症かの鑑別が困難だけでなく, BCG接種による陽性転化か否かの区別がつきがたい。よって感染防御免疫確立の指標とはならない。結核菌分泌タンパク

質抗原のプロテオーム解析が発展し, 結核菌主要タンパク質抗原の性質が解明されつつあり, その中に結核ワクチン抗原として有用なもの(HSP-65やAg85Bなど)や結核特異抗原として診断に有用な低分子分泌タンパク質抗原(ESAT-6やCFP-10など)が見出され, これらの刺激によるヒト末梢血リンパ球IFN- γ 産生能を測定する特異的な結核感染(細胞性)免疫診断法が開発され, ツベルクリン反応に代わるものとして注目されている。

はじめに

結核は, ハンセン病と並び人類始まって以来の長い関わりをもつ慢性伝染病で, 時代とともに蔓延衰退を繰り返してきた。化学療法発見以前には人類死亡原因の中で最高位を占め, 診断・治療・予防のあらゆる面で難病の第1とされた。20世紀後半, 衛生環

境の改善と抗結核薬の開発により結核罹患率は先進工業国で順調に減少を示しているが, 1980年代にAIDS合併症として再び増加傾向を示した。今日結核は, 大都市や高齢者, ホームレスなど社会的弱者, 医療関係者などデンジャーグループ特定集団に偏在する傾向があり, 世界でなお200万人を超える結核死が毎年報告されている。

I ツベルクリン反応と結核の診断法

結核の診断は, 基本的には菌の検出(染色や培養)により行われるが, 検出感度や迅速性から考えるとこれらの方法のみでは不十分であり, 遺伝子診断や臨床症状により総合的に診断される。免疫学的には結核に感染すると細

胞性免疫が成立するが、それを検出するのにツベルクリン反応(ツ反)が用いられる。Robert Kochは旧ツベルクリン(old tuberculin ; OT, 結核菌培養濾液を滅菌濃縮したもの)を用いて治療に応用しようとしたが、これは失敗に終わった。その後1907年、von PirquetがOTが結核の診断に役立つことを見出し、その後Mantouxが現在の皮内反応(Mantoux reaction)を始めた。1920年代Seibertらがツ反惹起活性成分がタンパク質抗原であることを示し、糖・核酸成分を除去した精製ツベルクリン(purified protein derivative ; PPD)として結核の診断やBCGで誘導される細胞性免疫の診断に用いられるようになった。PPDは結核菌が産生するストレスタンパク質[熱ショックタンパク質(heat shock protein ; HSP)やDnaK, GroEL, GroESなど]や分泌タンパク質(α 抗原)など、Tリンパ球に対する強い抗原性を示すタンパク質抗原を多数含んでいる。

ヒトではこの抗原液PPDを皮内に接種し、約48時間後にみられる局所の発赤や硬結の程度から結核感染の診断を行うものできわめて高い感度(97%以上)の診断法であるが、BCG接種によっても陽性転化するため、その判別が困難である。またツ反陽性化しても感染防御免疫が成立したことの証拠にはならない。PPDで惹起されるツ反は典型的な遅延型過敏症(delayed-type hypersensitivity ; DTH)で、血管拡張、浮腫、単核細胞浸潤がみられ、結核病巣の原型と考えられ、Th1型のCD4⁺T細胞の分裂増殖と活性化、機能分化が誘導される。感作T細胞の多くのクローンはPPDに含有

される数多くのタンパク質抗原に対してMHC (major histocompatibility complex)クラスII拘束性であり、特異的に反応して種々のT細胞サイトカインが産生される。一方、ツ反陽性が結核に対する感染防御免疫確立の証拠となるか否かはきわめて重要な問題である。R. Kochの時代からツ反型のDTH皮内反応は、結核菌に対する免疫応答としてTh1型の反応と認識されていることに変わりはないが、動物実験の結果をみるに限り、DTHと結核感染防御免疫とは必ずしも一致しない。DTHの発現なしに防御免疫の確立はありえないが、DTHの発現があれば防御免疫が十分とはいえない。現在わが国の制度下で実施されるBCG被接種者では最終的に90%近くの中・高校生がツ反陽性となっているにもかかわらず、15~20歳代の若年者集団に感染がみられることを考え併せると、BCG接種によってたとえツ反全てを陽性転化させても結核感染を100%防御することは困難である。わが国のように、BCG接種を制度的に採用している国々での大きな課題は、これまでのツ反が真に結核防御免疫の指標となるのかどうか、ということである。最近、結核感染防御免疫機構が次第に解明されて、結核防御免疫の発見に最も重要なTh1免疫誘導性サイトカインであるIFN- γ をPPDに特異的に反応して産生させ、T細胞の分化誘導の程度を定量的に調べる方法が報告された¹⁾²⁾。IFN- γ 産生性T細胞の主体はTh1型CD4⁺T細胞であるが、最近ではCD8⁺細胞にもこの機能をもつものが知られており、IFN- γ はマクロファージを活性化し、結核菌が示す

ファゴソームリソゾーム融合(phagosome-lysosome fusion ; P-L fusion)阻害効果の抑制と、iNOS誘導により合成されるNOラジカルがマクロファージ内で結核菌増殖を抑制することから、IFN- γ 産生能を診断の指標とすることは意義がある。最近、PPD特異的IFN- γ 定量キットが開発され皮内反応に代わるものとして試みられているが³⁾、ここでもPPDの高い交叉反応性が問題となった。

II 抗酸菌タンパク質抗原の多様性と結核診断

PPDがきわめて多種類のタンパク質抗原を含むことからわかるように、結核菌はきわめて多数のタンパク質抗原を合成する。しかも菌体内のみならず菌体外に分泌されるタンパク質抗原は、結核感染初期に宿主に免疫反応を惹起させる。結核菌および類縁抗酸菌が産生する代表的なタンパク質抗原を表1に示し、その特徴を述べる。

1. 65kDa HSP

結核菌をはじめ他の*Mycobacterium*属でも産生されるストレスタンパク質(HSP)で、大腸菌GroELとの相同性が高い。HSPは自然界に広く分布し、分類的に近縁の種の中ではかなりの構造類似性が保たれている。高温などストレス環境で産生量が増え、菌体内では複合体として存在する。分子内にヘリックス構造と疎水性領域を有し、T細胞に対して強い抗原性を示す。抗原エピトープは複数個存在し、結核菌特異的なものとmycobacteria共通のものがあるばかりでなく、哺乳類HSP抗

表1. 結核菌(および類縁抗酸菌)の主なタンパク質抗原

菌種	サブユニット サイズ(kDa)	名称(別名)	機能	免疫学的性質
<i>M. tuberculosis</i>	71	CIE Ag 63(DnaK)	熱ショックタンパク質; 大腸菌DnaKおよびヒト <i>hsp-70</i> と50%以上相似	マウスおよびヒト抗体と反応; 結核患者T細胞と増殖反応, 自己反応性抗原
<i>M. bovis</i> BCG	70	(DnaK)		
<i>M. leprae</i>	70	(DnaK)		マウスおよびヒト抗体と反応; 結核患者のCTLと増殖反応, $\gamma\delta$ T細胞により認識される
<i>M. tuberculosis</i>	65	CIE Ag 82(GroEL)	熱ショックタンパク質; 大腸菌GroELおよびヒト <i>hsp-60</i> と50%以上相似	
<i>M. bovis</i> BCG	65	64-kDa antigen (GroEL) MbaA, CIE Ag 82		<i>M. tuberculosis</i> complex特異的に患者血清抗体と反応; 結核患者およびBCG接種者のT細胞と増殖反応
<i>M. tuberculosis</i>	38	CIE Ag 78, Pab(PhoS) US Japan Ag 5	リン酸輸送における“結合タンパク質”; シグナルペプチドリポタンパク質コンセンサスあり; 糖タンパク質	モノクローナル抗体により認識される
<i>M. tuberculosis</i>	23	CIE Ag 62(SodA)	スーパーオキシドジスムターゼ; 大腸菌SodAおよびヒトミトコンドリアMnSodと50%以上相似	
<i>M. leprae</i>	28	(SodA)		
<i>M. tuberculosis</i>	12	(GroES)	熱ショックタンパク質 GroELと共同作用	モノクローナル抗体により認識される。 T細胞に対して強い増殖反応誘導
<i>M. bovis</i> BCG	12	MPB 57, BCG- α (GroES) MCP-1		
<i>M. leprae</i>	14	(GroES)		結節らいおよびレプロミンテストで反応陽性
<i>M. tuberculosis</i>	30/31	CIE Ag 85 antigen, P32, MPT 44	3~4種の分泌関連タンパク質をコードするmultigeneファミリーを形成; 成熟タンパク質ではシグナルペプチドは分解されている。最近Ag85A, B, Cの各タンパク質はミコリルトランスフェラーゼ活性をもつことがわかった	MAbsにより認識される。ハンセン病と結核患者抗体と交叉性, リウマチ性関節疾患患者の関節液とT細胞により認識される。フィブロネクチン結合活性を有し, 現在最もワクチン抗原として有望なタンパク質とされる
<i>M. bovis</i> BCG	30/31	CIE AG 85 A, MPB 44		
<i>M. bovis</i> BCG	30/31	CIE Ag 85B, MPB 59, α antigen, US Japan Ag 6		
<i>M. kansasii</i>	30/31	α Antigen, antigen $\alpha 2$	鉄調節タンパク質; 強いシグナル配列	らい腫型ハンセン病患者血清と反応
<i>M. leprae</i>	30/31			
<i>M. leprae</i>	28			
<i>M. bovis</i> BCG	23	MPB 64	<i>M. tuberculosis</i> complexに特有の主要分泌タンパク質	
<i>M. tuberculosis</i>	19	Lipoprotein	強力なシグナルペプチドおよびリビド部分をもつ。リポタンパク質	マウスおよびヒト抗体と反応; 患者T細胞と増殖反応
<i>M. bovis</i>	19			(同上)
<i>M. leprae</i>	18	L5	低分子熱ショックタンパク質群の1種	
<i>M. bovis</i> BCG	18	MPB 70 MPB 80	<i>M. bovis</i> の主要分泌タンパク質 シグナルペプチド; 20~25kDaの変異タンパク質あり; 糖タンパク質	<i>M. bovis</i> 感染で特異抗体と反応
<i>M. tuberculosis</i>	4~6	ESAT-6 family antigens	STCF(培養初期分泌タンパク質)	結核菌群(ヒト型菌および <i>M. bovis</i>)に含まれる最も特異的な抗原で感染防御抗原としてAg 85や19kDa抗原と合わせて最も可能性が高い
<i>M. bovis</i>		ESAT-6(1.7kbp DNA)	early secretory antigenic target-6の略。代表的な低分子T細胞抗原	
<i>M. kansasii</i>				
	10.4	TB10.4	ESAT-6とともにSTCFに含まれるAla-richタンパク質でBCG, MACにも存在	
	10	CFP-10	ESAT-6 family中, 最も強力な細胞性免疫抗原としてIFN- γ 誘導活性あり	結核患者, BCG陽転者と健常者の鑑別が可能
<i>M. tuberculosis</i>	7.3	TB7.3	Biotin結合部位あり, p13.8. ESAT-6 familyには属さず	IFN- γ 誘導能はやや低い。結核とBCG陽性の鑑別は困難
<i>M. bovis</i> BCG				
<i>M. auium</i>				

(文献6, その他より改変)

表2. *Mycobacterium* species内での低分子抗原 (*tb7.3*, *tb10.4*および*esat-6*)の分布

Species	Source	Distribution of the following gene			
		<i>tb7.3</i>	<i>tb10.4</i>	<i>cfp-10</i>	<i>esat-6</i>
<i>M. tuberculosis</i> H37Rv	ATCC 27294	+	+	+	+
<i>M. bovis</i> MNC27	SSI	+	+	+	+
BCG Danish 1331	SSI	+	+	-	-
BCG Tokyo	WHO	+	+	-	-
<i>M. avium</i>	ATCC 15769	+	+	-	-
<i>M. intracellulare</i>	ATCC 15985	+	+	-	-
<i>M. kansasii</i>	ATCC 12478	-	+	+	+
<i>M. marinum</i>	ATCC 927	+	+	+	+
<i>M. scrofulaceum</i>	ATCC 19275	-	-	-	-
<i>M. fortuitum</i>	ATCC 6841	-	-	-	-
<i>M. xenopi</i>	Isolated from a Danish patient	+	-	-	-
<i>M. szulgai</i>	Isolated from a Danish patient	+	-	+	+

(文献9より引用)




図1. 結核菌培養濾液タンパク質のSDS-PAGE分析パターン

*M. tuberculosis*は、0～42日までの種々の期間培養し、上清を濃縮後SDS-PAGEで分離した。染色は銀染色でタンパク質各バンドを検出した。

レーン1 (day 0), レーン2 (day 2), レーン3 (day 3), レーン4 (day 5), レーン5 (day 7), レーン6 (day 14), レーン7 (day 42), レーン8 (STCF), レーン9 (ESAT-6)

(文献5より引用)

原とも共通するエピトープを有することから、アジュバント関節炎やヒトの自己免疫疾患とも関連するのではないかと指摘されている。抗原決定基に非特異的な面が多いことから、ワクチン抗原としてはともかく、診断抗原としては適当でない。

2. 38kDaヒト型結核菌特異抗原

結核菌の種特異抗原の1つで、診断

用抗原としては重要なものの1つである。DanielとAnderson⁴⁾は antigen 5 と命名された38kDaタンパク質抗原を単離し、これが糖鎖を含む糖タンパク質抗原であることを明らかにした。このタンパク質は *M. tuberculosis* と *M. bovis* に特異的に産生され、感作モルモットと結核患者のTおよびBリンパ球に増殖反応を引き起こすが、ヒトの皮膚反応ではモルモットと比べて種特

異性が低い。それでもこの抗原は、結核感染に対する体液性免疫反応においては分泌抗原としてELISA法では最も反応性が高いとされている。

3. Antigen 85 complex (α抗原)

結核菌タンパク質抗原中、最も特徴的な機能をもつ成分の1つで3種の類似タンパク質(85A, 85Bおよび85C)からなる。おのおの別個の遺伝子によ




図2. 結核患者、PPD陽転者、BCG接種者の結核菌各種抗原に対する細胞性免疫反応性の比較
結核患者(37名)、PPD陽転者(12名)、BCG接種者(14名、うち10名PPD陽性)および健常者(8名、PPD陰性、BCG非接種)の末梢血PBMCを各抗原で刺激し、上清中のIFN- γ を測定してTリンパ球の活性とした。
MTB sonicateに対しては、結核患者(TB)、PPD陽転者(PPD conv.)、BCG接種者(BCG)のいずれもが同程度反応、ST-CFではBCG接種者の反応性が低下する。ESAT-6ではBCGとPPD conv.の反応性が低下する。CFP-10では、BCG、PPD conv.の反応性が著しく低下し、活動性結核患者のみ陽性となる。

A: MTB超音波処理上清抗原, B: MTB-ST-CF抗原, C: ESAT-6抗原, D: CEF-10抗原, IFN- γ 産生

(文献7より引用)

りコードされているがエピトープは共通しており、それぞれのタンパク質の性質も共通点が多い。このうち85B抗原は α 抗原(antigen 6, MPB59/MPT 59など)と呼ばれ、分子量30kDaで発育菌から分泌され、その産生量も多い。30kDaタンパク質遺伝子は*M. bovis*と*M. kansasii*からクローニングされたが、この抗原は全ての*Mycobacterium*属菌種に存在する他ミコール酸を合成する近縁菌にも広く分布する。種特異的および属共通のエピトープを有し、mycoloyl transferase活性があり細胞壁合成に必須である。30kDaタンパク質は感作動物にはPPD以上に高い特異性で皮膚反応を引き起こし、またIgG抗体も活動性結核の血清診断に有用とされるが交叉反応性は高い。Th1型免疫誘導抗原として結核感染健常者のT細胞と強く反応するが、活動性結核患者のリンパ球との反応は弱く、リンパ球増殖反応の弱い宿主ほど結核が発病しやすく進行しやすい。*in vitro* IFN- γ とTNF- α 産生を誘導し、これはフィブロネクチン結合を介して起こるとされる。結核ワクチン抗原としては最も強力なものと考えられる。

4. 低分子分泌タンパク質抗原(表2)

結核菌(振盪)培養初期に分泌される低分子タンパク質(short term culture filtrate ; STCF)は、最近結核の特異的診断用抗原として注目される強力なT細胞エピトープをもつ抗原である(図1)⁵⁾⁶⁾。この代表的なものがESAT-6(early secretory antigenic target-6)で、モノクローナル抗体による分析結果から、これらは分子量が不均一で3~31kDaに及ぶ単純タンパ




図3. 異なった患者末梢血単球からのT-cell line(TCL-1, TCL-2およびTCL-3)のPPD, rESAT-6およびrCFP-10に対する反応性
結核患者由来の結核菌特異的Tリンパ球のPPD, rESAT-6およびrCFP-10各抗原に対する増殖活性は、患者によって異なり、ESAT-6抗原(whole antigenおよびpeptide mixture)に高い反応性を示すもの、CFP-10(whole antigenおよびpeptide mixture)に高い反応性を示すもの、両者に高い反応性を示すものなどさまざまであるが、PPDには普遍的に反応するものが多い。この理由は宿主側の抗原認識様式が遺伝的に支配されており(HLA型など)、抗原の種類によって提示されやすさに個人的な差があるためと考えられる。このことから、混合抗原は単一抗原より高い感度を示すこととなり、したがって多重抗原診断法が有利な理由となる。(文献8より引用)

表3. 結核専門病院を受診した初診患者(210名)の, 6種の脂質抗原に対する血清IgG抗体陽性率と喀痰中結核菌排菌量の影響

Gaffky numbers	Antigens						total*
	TDM-T	TDM-I	TMM-T	TMM-I	PL-1	PL-2	
G-0 (n=25)	17 (68.0%)	17 (68.0%)	12 (48.0%)	12 (48.0%)	18 (72.0%)	21 (84.0%)	24 (96.0%)
G(+1~+3) (n=29)	18 (62.0%)	14 (48.3%)	11 (37.9%)	11 (37.9%)	18 (62.0%)	21 (72.4%)	26 (89.7%)
G(+4~+8) (n=88)	62 (70.5%)	47 (53.4%)	67 (76.1%)	48 (54.5%)	63 (71.6%)	68 (77.3%)	81 (92.0%)
G(+9 or +10) (n=43)	36 (83.7%)	32 (74.4%)	32 (74.4%)	30 (69.8%)	31 (72.1%)	35 (81.4%)	42 (97.7%)
Gaffky unknown (n=25)	22 (88.0%)	17 (68.0%)	21 (84.0%)	12 (48.0%)	19 (76.0%)	17 (68.0%)	23 (92.0%)
total (n=210, 100%)	155 (73.8%)	127 (60.5%)	143 (68.1%)	113 (53.8%)	149 (70.9%)	162 (77.1%)	196 (93.3%)

* 6種の抗原(TDM-T, TDM-I, TMM-T, TMM-I, PL-1, PL-2)のうちのいずれか1種以上に陽性となったものを結核(発病)陽性と算定した場合, 93.3%の高い陽性率(感度)が得られる。(文献11より引用)

ク質でタンパク質自体の不均一性または重合度差によって区別されるとされる。類似のタンパク質にCFP-10, TB10.4がある。ESAT-6は*M. tuberculosis*および*M. bovis*に存在するRD-1遺伝子にコードされ, BCG株にはRD-1欠損があるため産生されない。*M. kansasii*, *M. marinum*および*M. smegmatis*には遺伝子が存在し, TB10.4, CFP-10とともにタンパク質の発現もみられる。これまで用いられてきたツ反は, 結核感染による陽性反応かBCG接種による陽転かの鑑別は不可能であるが, このような結核菌特異抗原を用いた細胞性免疫反応を指標とすることにより, 結核患者(発病者), 結核感染者(未発病者)およびBCG陽転者の正確な診断が可能となるものと思われる(図2)⁷⁾⁻⁹⁾。QuantIFERON® TB-2Gなどの測定用キットが最近開発された。ただ, さらに残った問題は, このような精製タンパク質抗原を用いた場合, これらの単独抗原に対する宿主(ヒト)免疫応答がHLA型などにより異なることで(図3)⁹⁾, 診断感度を高めるためには複数抗原を組み合わせた多重抗原診断法が必要になるものと

考えられる。

おわりに

最近, タンパク質抗原と比べて結核菌表層脂質抗原に対する抗体反応が活動性結核の診断に有用であることが報告されつつあり(表3)¹¹⁾, 発病や化学療法による治療経過によく一致することとMHC拘束性をもたないことから, 反応は普遍性が高く, 結核の診断にはプロテオミクスに基づく抗原解析と併せてリビドミクス解析による診断法が発展することも期待される。

文献

- 1) Kawamura I, Tsukada H, Yoshikawa H, et al : IFN- γ -producing ability as a possible marker for the protective T cells against *Mycobacterium bovis* BCG in mice. *J Immunol* 148 : 2887-2893, 1992
- 2) Flynn JL, Chan J, Triebold K, et al : An essential role for interferon γ in resistance to *Mycobacterium tuberculosis* infection. *J Exp Med* 178 : 2249-2254, 1993
- 3) Pottumarthy S, Morris AJ, Harrison AC, et al : Evaluation of the tuber-

culin γ interferon assay ; Potential to replace the Mantoux skin test. *J Clin Microbiol* 37 : 3229-3232, 1999

- 4) Daniel TM, Anderson PA : The isolation by immunoabsorbent affinity chromatography and physicochemical characterization of *Mycobacterium tuberculosis* antigen 5. *Am Rev Respir Dis* 117 : 533-539, 1978
- 5) Andersen P, Askgaard D, Ljungqvist L, et al : Proteins released from *Mycobacterium tuberculosis* during growth. *Infect Immun* 59 : 1905-1910, 1991
- 6) Andersen P : Host responses and antigens involved in protective immunity to *Mycobacterium tuberculosis*. *Scand J Immunol* 45 : 115-131, 1997
- 7) Arend SM, Andersen P, van Meijgaarden KE, et al : Detection of active tuberculosis infection by T cell responses to early-secreted antigenic target 6-kDa protein and culture filtrate protein 10. *J Infect Dis* 181 : 1850-1854, 2000
- 8) Arend SM, Geluk A, van Meijgaarden KE, et al : Antigenic equivalence of human T-cell responses to *Mycobacterium tuberculosis*-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic pep-

-
- tides. *Infect Immun* 68 : 3314-3321, 2000
- 9) Skjot RL, Oettinger T, Rosenkrands I, et al : Comparative evaluation of low-molecular-mass proteins from *Mycobacterium tuberculosis* identifies members of the ESAT-6 family as immunodominant T-cell antigens. *Infect Immun* 68 : 214-220, 2000
- 10) van Pinxteren LA, Ravn P, Agger EM, et al : Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10. *Clin Diagn Lab Immunol* 7 : 155-160, 2000
- 11) Fujita Y, et al : 肺結核 ; 抗抗酸菌抗体 (Development of serodiagnostic tests for active tuberculosis and acid-fast bacteria). *綜合臨* 52 : 135-142, 2003

矢野 郁也

昭和34年 大阪市立大学医学部卒業

現在, 日本ビーシージー製造株式会社

中央研究所所長

専門分野 : 細菌学, 免疫学, 結核病学



ELSEVIER

Journal of Immunological Methods 298 (2005) 21–34

JIM
Journal of
Immunological Methods

www.elsevier.com/locate/jim

Research paper

Expression mapping using a retroviral vector for CD8⁺ T cell epitopes: Definition of a *Mycobacterium tuberculosis* peptide presented by H2-D^d

Taiki Aoshi, Mina Suzuki, Masato Uchijima, Toshi Nagata, Yukio Koide*

Department of Microbiology and Immunology, Hamamatsu University School of Medicine, 1-20-1 Handa-yama, Hamamatsu 431-3192, Japan

Received 23 June 2004; received in revised form 29 November 2004; accepted 17 December 2004

Available online 1 February 2005

Abstract

Identification of CD8⁺ T cell epitopes is important because detection of specific CD8⁺ T cells after infection or immunization requires prior knowledge of epitope specificity. Furthermore, identification of CD8⁺ T cell epitopes permits the development of specific preventive and therapeutic approaches to both infections and tumors. Thus far, CD8⁺ T cell epitopes have been identified either using an overlapping peptide library covering an entire protein, or using algorithms designed to identify likely peptides that bind to major histocompatibility complex (MHC) class I molecules. The synthesis of overlapping peptides can be prohibitively expensive, and the algorithm programs used to predict CD8⁺ T cell epitopes are not always accurate. Here we describe a retroviral expression system that specifically allows longer polypeptides and shorter peptides to be expressed in the cytoplasm, and thereby to be processed onto class I MHC molecules. T cells from mice that were immunized with a DNA vaccine encoding MPT-51 were probed against MHC-compatible cell lines retrovirally transduced with overlapping gene fragments encoding 120–140 amino acids of the MPT-51 molecule. After further testing of shorter peptide sequences, we identified a CD8⁺ T cell epitope using cell lines expressing a relatively small number of algorithm-predicted candidate epitopes. We found that one of the requirements for cell surface display of the 20-mer peptide was the need for cotranslational ubiquitination. The restriction molecule was identified as D^d following transduction with MHC class I genes followed by transduction with the oligonucleotide encoding the epitope. The retroviral expression system described here is cost-effective, particularly if the target molecule is large, and could be adapted to identifying T cell epitopes recognized in infectious disease and against tumor cell antigens.

© 2005 Elsevier B.V. All rights reserved.

Keywords: Epitope mapping; CD8⁺ T cells; Retroviral expression system; Algorithm

Abbreviations: aa, amino acid; CTL, cytotoxic T lymphocytes; ELISA, enzyme-linked immunosorbent assay; ELISPOT, enzyme-linked immunosorbent spot assay; IOFCS, 10% heat-inactivated fetal calf serum; HRP, horseradish peroxidase; MHC, major histocompatibility complex; mAb, monoclonal antibody; PBS, phosphate-buffered saline; RT, reverse transcription; TAP, transporter associated with antigen processing.

* Corresponding author. Tel.: +81 53 435 2334; fax: +81 53 435 2335.

E-mail address: koideib@hama-med.ac.jp (Y. Koide).

0022-1759/\$ - see front matter © 2005 Elsevier B.V. All rights reserved.

doi:10.1016/j.jim.2004.12.015

1. Introduction

CD8⁺ cytotoxic T lymphocytes (CTL) play a pivotal role in protective immunity against infection with intracellular pathogens, such as certain bacteria and viruses (Uchijima et al., 1998; Flynn and Chan, 2001; Gulzar and Copeland, 2004). During an infection, many proteins derived from the pathogen are secreted or produced in the host cells. These proteins are processed by the MHC class I pathway. The endogenous MHC class I pathway targets cytosolic proteins, either self-derived or pathogen-derived, that are processed to peptides by the proteasome. The resulting peptides are actively transported into the endoplasmic reticulum by transporter associated with antigen processing (TAP) molecules, and are finally presented to CTL in the context of MHC class I molecules (Ortmann et al., 1994; Heemels and Ploegh, 1995). Following CTL recognition of pathogen-derived MHC/peptides complexes on the cell surface, the infected cells are killed and infection eliminated by the secretion of effector molecules, such as perforin, granzyme, and interferon- γ (Barry and Bleackley, 2002).

Although intracellular pathogens possess a large number of peptides which have the potential to bind to MHC class I molecules, the CD8⁺ T cell response is more limited, with only a minority of the potential binding motif-containing peptides from a given foreign protein being actually immunogenic (Sercarz et al., 1993; Barber and Parham, 1994). Various factors have been implicated in this limitation (epitope selection): (1) antigen processing by the proteasome (Eggers et al., 1995; Niedermann et al., 1996); (2) TAP-dependent peptide transport (Lauvau et al., 1999); (3) affinity of the peptide for the MHC (Chen et al., 1994; Sette et al., 1994); (4) the transport of MHC/peptide complexes to the cell surface (Levitsky et al., 1997); and (5) the response of the T-cell repertoire (Connolly, 1994; Cao et al., 1996).

To better understand CD8⁺ T cell responses during infection, it is important to identify epitopes that are recognized by CD8⁺ T cells. Identification of the epitopes, which typically consist of 8–10-mer peptides, is essential to detect specific CD8⁺ T cells by the tetramer assay (Altman et al., 1996), intracellular cytokine staining, or the enzyme-linked immunosorbent spot assay (ELISPOT). In addition, identi-

fication of these epitopes permits the development of specific preventive and therapeutic approaches in both infectious disease and cancer (Nagata et al., 2004; Chen et al., 2004; Faure et al., 2004; Romero et al., 2004).

Overlapping peptide libraries have been widely employed for the identification of T cell epitopes. The libraries, consisting of 15–20-mer peptides overlapping by at least nine residues, span the whole protein of interest (Van der Zee et al., 1989). Once a T cell epitope has been mapped in a 15–20-mer peptide, the minimal T cell epitope can be delineated by preparing a set of peptides, which have been truncated from the N- or C-terminal end of the known active peptide. This is a very powerful method for mapping T cell epitope(s), but it requires numerous rounds of peptide synthesis, which can be prohibitively expensive for a large protein.

Recently, a number of programs that utilize algorithms that have been useful in predicting T cell epitopes for peptide mapping studies have been developed (Parker et al., 1994; Rammensee et al., 1999; Reche et al., 2002). These programs list and rank the possible candidates of T cell epitopes within a given protein sequence. However, it has been shown that these program methods are not infallible, and in some cases are no better than the use of the simple anchor residue motifs (Andersen et al., 2000). In general the immunogenicity of individual peptides predicted by such programs must be confirmed empirically, using any number of T cell assays, although some programs have incorporated various factors involved in the epitope processing (Peters et al., 2003). Currently, the combination of an overlapping peptide library with an epitope prediction program seems to be the most comprehensive and effective method for identification of CD8⁺ T cell epitopes within a protein (Suzuki et al., 2004).

In this report, we describe a novel cost-effective retroviral expression method for the identification of CD8⁺ T cell epitopes within antigens of interest. As a model antigen, we used MPT51, a major secreted protein of *Mycobacterium tuberculosis* (Wilson et al., 2004), since we recently demonstrated that MPT51 can induce T-cell-mediated immune responses and protective immunity upon challenge with *M. tuberculosis* (Miki et al., 2004). The retroviral expression system makes it possible to express large DNA

fragments in cells so that the location of CD8⁺ T cell epitopes can be rapidly identified without preparing numerous synthesized peptides. Minimal CD8⁺ T cell epitopes can be identified from the candidate DNA fragments using a computer-assisted algorithm. This method is particularly useful for mapping epitopes from large target molecules where the cost of synthesizing peptides is particularly high.

2. Materials and methods

2.1. Mice

BALB/c mice (Japan SLC, Hamamatsu, Japan) were kept under specific pathogen-free conditions and fed autoclaved food and water ad libitum at the Institute for Experimental Animals, Hamamatsu University School of Medicine. Two-month-old female mice were used in all experiments. All animal experiments were performed according to the Guidelines for Animal Experimentation, Hamamatsu University School of Medicine.

2.2. Cell lines

P815 mastocytoma cell line (H2^d) and BW5147 T lymphoma cell line (H2^k) were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum (RPMI/10FCS) in a humidified atmosphere of 5% CO₂.

2.3. Construction of a plasmid DNA vaccine, pCI-MPT51

The DNA encoding the mature MPT51 molecule (D26486) was amplified from a plasmid, pMB49 (Ohara et al., 1995), by PCR with following primer pairs: forward primer with ATG starting codon, 5'-CCTCTAGAATGGCCCATACGAGAACCTGA-3'; reverse primer with stop codon, 5'-CAGGCTCTAGACATCGGCACCTGGCTTAGC-3' (underlined nucleotides indicate *Xba*I site). The PCR fragment was digested with *Xba*I and inserted into the *Xba*I site located downstream to the CMV immediate-early enhancer/promoter region of an expression plasmid pCI (Promega, Madison, WI). The nucleotide sequence was confirmed by automated DNA sequenc-

ing (ABI PRISM 310 Genetic Analyzer; Applied Biosystems, Foster City, CA) using a dye primer cycle sequencing kit (Applied Biosystems).

2.4. Construction of retroviral expression library

Three overlapping DNA fragments encoding fragments of the 266-amino acid (aa) mature MPT51 molecule of *M. tuberculosis* were generated from pCI-MPT51 by PCR amplification using the following primer pairs: for MPT51-F1 encoding aa 1–140, 5'-CCTCTAGAATGGCCCATACGAGAACCTGA-3' (forward primer) and 5'-GTTCTAGATTAGTACAAAAGCCCGACATC-3' (reverse primer); for MPT51-F2 encoding aa 78–198, 5'-ACTCTAGAAATGGATGGCAGCAAGCAGTG-3' and 5'-CCTCTAGATTACGGGTCCACACCCACACC-3'; and for MPT51-F3 encoding aa 135–266, 5'-CTTCTAGAATGTCTGGGCTTTTTGTA-3' and 5'-CAGGCTCTAGACATCGGCACCTGGCTTAG-3' (the forward primers have the ATG starting codon, while the reverse primers contain the TAA stop codon; underlined nucleotides indicate the *Xba*I site). The PCR fragments were digested with *Xba*I and inserted into the *Xba*I site of pBluescript II SK(–) (Stratagene, La Jolla, CA), the orientation of DNA fragments was confirmed by DNA sequencing, and then *Xho*I–*Not*I fragments were cloned into the retroviral expression vector, pDON-AI (Takara Bio, Tokyo, Japan), the multiple cloning site of which had been modified by us. Furthermore, DNA fragments encoding aa 1–100 of the mature MPT51 were amplified by PCR as 40 aa peptide stretches overlapping by 20 residues. The primer pairs used were as follows: for MPT51 1–40, 5'-CCTCTAGAATGGCCCATACGAGAACCTGA-3' and 5'-CCTCTAGATTAATCCGGGCCGGCGTTGAAG-3'; for MPT51 21–60, 5'-CCTCTAGAATGTTCCCTAGCCGGTGGCCGC-3' and 5'-CCTCTAGATTACGAAATCCCCTTGCCCGCC-3'; for MPT51 41–80, 5'-CCCTCTAGAATGGTCAGTAACTGGGTCCG-3' and 5'-CCTCTAGATTAGCTGCATCCTGCTCCCAG-3'; for MPT51 61–100, 5'-CCTCTAGAATGGTGGTGGCA CCGCCGGTG-3' and 5'-CCTCTAGATTAGCCCCGGTTAGCGGC-CAGC-3'. The resultant PCR products were inserted into pDON-AI after cloning into pBluescript II SK(–) as described above.

Forward and reverse primers for MPT51 1–20, MPT51 21–40, and MPT51 41–60 were synthesized, annealed, and then inserted into the *Xba*I site of pDON-AI. The nucleotide sequences of the oligonucleotides were as follows:

MPT51 1–20 (forward) 5'-CTAGAATGGCCCC-CRACGAGAACCTGATGGTGCCCAGCCC-CAGCATGGGCAGGGACATCCCCGTGGCC-TAAT-3';

MPT51 1–20 (reverse) 5'-CTAGATTAGGC-CACGGGGATGTCCCTGCCCATGCTGGGGC-TGGGCACCATCAGGTTCTCGTAG-GGGGCCATT-3';

MPT51 21–40 (forward) 5'-CTAGAATGTTC-CTGGCCGGCGGCCCCACGCCGTGTA-CTGCTGGACGCCTTCAACGCCGGCCC-GACTAAT-3';

MPT51 21–40 (reverse) 5'-CTAGATTAGTCGG-GGCCGGCGTTGAAGGCGTCCAGCAGGTA-CACGGCGTGGGGGCCGGCCAGGAA-CATT-3';

MPT51 41–60 (forward) 5'-CTAGAATGGTGAG-CAAGTGGGTGACCGCCGGAACGCCAT-GAACACCCTGGCCGGCAAGGGCATCAGC-TAAT-3';

MPT51 41–60 (reverse) 5'-CTAGATTAGCT-GATGCCCTTGCCGGCCAGGGTGTT-CATGGCGTTGCCGGCGGTACCCAGTTGCT-CACCATT-3'.

In some experiments, the ubiquitin gene was fused to the 5' side of the above DNA fragments encoding the 20-aa length peptides. The ubiquitin gene was amplified from mouse cDNA with a forward primer (5'-TCACTAGTATGCAGATCTTCGTG AAGAC-3'; underline indicates the *Spe*I site) with the ATG starting codon and a reverse primer (5'-AATCTAGA CACCACACCTCTCAGGCGA AG-3'; underline indicates the *Xba*I site). Using the reverse primer, a glutamine residue at aa number 76 (G₇₆) normally present in the ubiquitin protein was changed to a valine (V₇₆) to avoid cleavage with deubiquitinase. After digesting the PCR product with *Spe*I and *Xba*I, the ubiquitin gene was inserted into pBluescript II SK(-) and then the DNA fragments encoding the MPT51 20-mers were inserted in the *Xba*I site to obtain ubiquitin/MPT51 20-mer fusion products. The

fused product was cut out with *Xho*I and *Not*I, and inserted in the *Xho*I–*Not*I site of a retroviral expression vector, pDON-AI. H2-K^d, H2-D^d, and H2-L^d cDNA fused with the EGFP gene were also cloned into a retroviral vector.

The nucleotide sequences of the recombinant plasmids were confirmed by DNA sequencing using an ABI PRISM 310 genetic analyzer. Large-scale purification of expression vectors was achieved using a Qiagen Plasmid Mega kit system (Qiagen, Chatsworth, CA) and endotoxin was removed by Triton X-114 phase separation.

2.5. Retroviral infection and selection of G418-resistant transformants

Retroviral supernatant was generated by transfecting recombinant pDON-AI proviral constructs into the Phoenix ecotropic packaging cell line (purchased from the American Type Culture Collection, Manassas, VA, and used with the permission of Dr. G.P. Nolan, Stanford University School of Medicine, CA) according to Dr. Nolan's protocol (Grignani et al., 1998). A confluent 100-mm plate of retrovirus-producing cells was maintained in DMEM/10FCS. After 2 days, the culture supernatant contain-




Fig. 1. P815 cells retrovirally transduced with gene encoding mature MPT51 stimulate splenocytes from BALB/c mice following gene gun immunization with pCI-MPT51. The immune splenocytes were stimulated with either wild-type P815 cells or MPT51-expressing P815 cells for 24 h and IFN- γ concentrations were measured by ELISA. Data are presented as the mean \pm S.D. of triplicate wells. All data are representative of at least three independent experiments.

ing the retrovirus was used to infect P815 cells in the presence of 8 $\mu\text{g/ml}$ polybrene (Sigma-Aldrich Japan, Tokyo, Japan). After 16 h, the P815 cells were washed in phosphate-buffered saline (PBS) and cultured in the presence of 400 $\mu\text{g/ml}$ G418. After 2–3 weeks, surviving stable transformants were obtained and used for the study.

2.6. Semi-quantitative reverse transcription (RT) PCR

RT-PCR was performed as described previously (Yoshida et al., 1995). Total RNA was prepared from the G418-resistant transformants using ISOGEN

(Nippon Gene, Tokyo, Japan) according to the manufacturer's instructions. Single-stranded cDNA was synthesized with SuperScript II reverse transcriptase (Gibco BRL) and then used for PCRs. The PCR products were separated by 8% polyacrylamide gel electrophoresis and visualized by staining with ethidium bromide (Sigma-Aldrich Japan). The images were recorded using a densitograph AE-6900M (ATTO, Tokyo, Japan). The sequences of the primers used in this study were as follows:

Primer pairs for MPT51-F1, MPT51-F2, and MPT51-F3 were described above.




Fig. 2. Identification of fragments of a portion that contains a T cell epitope(s). (A) Regions of MPT51 protein, F1, F2, and F3 that were cloned into the retroviral expression vector. The numbers next to the indicated fragments correspond to the amino acid numbers of mature MPT51 protein. (B) P815 cells were infected with retroviruses encoding the indicated MPT51 fragments and G418-resistant stable transformants were obtained. Then, mRNA expression of the MPT51 gene, and MPT51F1, MPT51F2, and MPT51F3 gene fragments in the transformants were assessed by RT-PCR analysis. *Neo* and G3PDH mRNA expression were also assessed by RT-PCR. (C) The immune splenocytes were stimulated with either wild-type P815 cells or MPT51 fragment-expressing P815 cells for 24 h, and IFN- γ concentrations were measured by ELISA. Data are presented as the mean \pm S.D. of triplicate wells. All data are representative of at least three independent experiments.

Neo forward 5'-CGACCTGTCCGGTGCCCT-GAATGAA-3';

Neo reverse 5'-GTCCCTTCCCGCTTCAGTGA-CAACG-3';

G3PDH forward 5'-ACCACAGTCCATGCCAT-CAC-3';

G3PDH reverse 5'-TCCACCACCCTGTT-GCTGTA-3'.

2.7. Immunization of mice

Mice were immunized by employing a gene gun system with a plasmid DNA vaccine encoding the mature MPT51 molecule. For DNA immunization with the Helios gene gun system (Bio-Rad Laboratories, Hercules, CA), DNA-coated gold particles were prepared according to the manufacturer's

instruction manual. The gold particles were coated with plasmid DNA in a ratio of 0.5 mg gold particles/1 μ g DNA. To immunize the mice, the shaved abdominal skin area was wiped with 70% ethanol. The spacer of the gene gun was held directly against the abdominal skin, and the device was discharged at a helium discharge pressure of 400 psi. Each mouse received two immunizations containing 1 mg of plasmid DNA-coated gold particles in total.

2.8. Preparation of splenocyte culture supernatants for evaluation of IFN- γ production

Spleen cell suspensions (1×10^6 cells/well) from mice immunized with a DNA vaccine encoding the MPT51 protein were stimulated by P815 stable




Fig. 3. MPT51 1–60 contains a T cell epitope(s). (A) Four 40-mer fragments of MPT51 overlapping 20 aa were cloned into the retroviral expression vector. (B) The immune splenocytes were stimulated with the P815 cells expressing the indicated 40-mer and IFN- γ concentrations were measured by ELISA. Data are presented as the mean \pm S.D. of triplicate wells. All data are representative of at least three independent experiments.




Fig. 4. Epitope expression on the 20-mer of MPT51 requires ubiquitination. (A) Three 20-mer fragments of MPT51 were inserted into the retroviral vector. (B) The immune splenocytes were stimulated with the P815 cells expressing the indicated 20-mer, and IFN- γ concentrations were measured by ELISA. (C) Construction of cotranslational ubiquitination of the 20-mer fragments. (D) The immune splenocytes were stimulated with the P815 cells expressing the ubiquitinated 20-mer and IFN- γ concentrations were measured by ELISA. Data are presented as the mean \pm S.D. of triplicate wells. All data are representative of at least three independent experiments.

transformants (2.5×10^4 per well) in RPMI/10FCS in 96-well plates at 37 °C in 5% CO₂. The IFN- γ concentration was measured by a sandwich enzyme-linked immunosorbent assay (ELISA).

2.9. Quantification of IFN- γ with cytokine ELISA

IFN- γ production was measured by ELISA. The 96-well ELISA plates (EIA/RIA Plate A/2; Costar, Cambridge, MA) were coated with 2 μ g/ml capture antibody (anti-murine IFN- γ monoclonal antibody (mAb) R4-6A2; BD PharMingen, San Jose, CA) at 4 °C overnight, washed with PBS containing 0.05% Tween-20, and blocked with Block Ace (Dainippon Seiyaku, Tokyo, Japan) at 37 °C for 2 h. After washing, the culture supernatant to be tested and IFN- γ standards were added to the plates and incubated at 4 °C overnight. After further washing, 0.5 μ g/ml biotin-labeled anti-murine IFN- γ detection mAb (XMG1.2; BD PharMingen) was added to the plates, which were then incubated at room temperature for 1 h. After washing the plates, 0.1 μ g/ml horseradish peroxidase (HRP)-conjugated streptavidin (Vector Laboratories, Inc., Burlingame, CA) was added, followed by a 30-min incubation at room temper-

ature. After washing, bound HRP-conjugated streptavidin was detected using the substrate 3-, 3'-, 5-, 5'-tetramethylbenzene dihydrochloride (Sigma-Aldrich Japan). After 5 min, the enzyme reaction was stopped by adding 2 M H₂SO₄, followed by measuring the absorbance at 450 nm using an EZS-ABS Microplate Reader (Iwaki, Tokyo, Japan).

2.10. Analysis of CD8⁺ T cells using H2-D^d-peptide tetramer complexes

An H2-D^d-peptide tetramer complex was kindly supplied by the NIH Tetramer Facility. Spleen cells

Table 1
Candidates of T cell epitope in MPT51 21–40

	Prediction score (9-mer)							
	SYPEITHI		BIMAS			RANKPEP		
	K ^d	L ^d	K ^d	D ^d	L ^d	K ^d	D ^d	L ^d
21–29				0.4		25.0		
23–31	16.0	15.0	57.6	20.0	5.0	10.0	103.0	53.0
24–32	13.0	12.0	48.0	400.0	7.5		76.0	40.0
25–33		13.0					35.0	48.0
27–35				0.4	10.0			
29–37	20.0		120.0			34.0		